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Polybrominated diphenyl ethers (PBDEs) are
ubiquitous environmental contaminants that
are found in both abiotic and biotic environ-
mental samples (Hites 2004; Streets et al.
2006). PBDEs are used as ﬂame retardants; the
three main commercial types of PBDE are
penta-BDE, octa-BDE, and deca-BDE.
DE-71, a widely used commercial penta-BDE
product, is generally composed of 50–60%
penta-BDE congeners, 24–38% tetra-BDE
congeners, and 4–8% hexa-BDE congeners
(Birnbaum and Staskal 2003). Since the 1970s,
penta-BDE has been used as a ﬂame retardant
in polyurethane foam–containing consumer
goods such as carpet padding, sofas, and mat-
tresses; this ﬂame retardant can account for up
to 30% by weight of the foam (Hale et al.
2002). DE-71 also has minor uses in phenolic
resins, polyesters, and epoxy. Despite its
relatively small global production and usage
compared with deca-BDE, the congeners
in penta-BDE, such as 2,2´,4,4´-tetra-
bromodiphenyl ether (BDE-47), 2,2´,4,4´,5-
pentabromodiphenyl ether (BDE-99), and
2,2´,4,4´,5,5´-hexabromodiphenyl ether
(BDE-153), are the most common PBDE
congeners found in environmental samples,
especially in biotic samples (Hites 2004), sug-
gesting that these congeners are persistent and
bioaccumulative. 
Although the toxicity of PBDEs is not well
understood, these compounds may be neuro-
toxic, thyrotoxic, estrogenic, and carcinogenic
(Siddiqi et al. 2003). Their toxicity might be
due to hydroxylated PBDE metabolites
(HO-PBDEs) formed in animals. Although
HO-PBDEs are less persistent than PBDEs,
they may have more severe biological effects.
For example, HO-PBDEs have thyroxine-like
and estrogen-like chemical structures (Meerts
et al. 2001), and thyroid hormone–like
HO-PBDE congeners have been shown to
bind competitively with human transthyretin
(TTR), a transport protein for the thyroid
hormones, thyroxine and thyronine (Meerts
et al. 2000). The competitive binding of
HO-PBDE to TTR provides a mechanism
that can potentially result in disrupted
thyroxine homeostasis. Putative PBDE
metabolites are able to activate an estrogen-
responsive luciferase reporter gene construct
(Meerts et al. 2001). 
Our research has shown that DE-71 acts
as a weak estrogen in cultured human breast
cancer cells and in ovariectomized mice
(Mercado-Feliciano M, Bigsby RM, unpub-
lished data). Cell proliferation was increased
when MCF-7 cells were cultured in the pres-
ence of DE-71 for 10 days. When DE-71 was
administered to mice for 34 days, the uterine
weight, uterine epithelial height, and vaginal
epithelial thickness increased slightly.
However, short-term treatment of cultured
cells or mice showed very little estrogenic
effect. These observations suggest that accu-
mulation of DE-71 metabolites may be
involved in these estrogenic effects. Therefore,
we conducted the present study to identify
and quantify metabolites of DE-71 formed
during in vivo treatment of mice. Based on
these results, three metabolic pathways are
proposed.
Materials and Methods
Chemicals. We obtained commercial DE-71
from the Great Lakes Chemical Corporation
(West Lafayette, IN). Dimethyl sulfoxide and
β-estradiol-3-benzoate were purchased from
Sigma Chemical Co. (St. Louis, MO), and
corn oil was purchased from ICN Biomedicals
(Aurora, OH).
We purchased all of the neutral standards
(BDEs 28, 47, 71, 77, 85, 99, 100, 153, 154,
183, and 1,3,5-tribromobenzene) from
AccuStandard (New Haven, CT). 4´-HO-
2,2´,4-Tri-BDE (4´-HO-BDE-17); 2´-HO-
2,4,4´-tri-BDE (2´-HO-BDE-28); 4-HO-
2,2´,3,4´-tetra-BDE (4-HO-BDE-42);
3-HO-2,2´,4,4´-tetra-BDE (3-HO-BDE-47);
5-HO-2,2´,4,4´-tetra-BDE (5-HO-BDE-47);
6-HO-2,2´,4,4´-tetra-BDE (6-HO-BDE-47);
4´-HO-2,2´,4,5´-tetra-BDE (4´-HO-BDE-
49); 2´-HO-2,3´,4,4´-tetra-BDE (2´-HO-
BDE-66); and 2´-HO-2,3´,4,5´-tetra-BDE
(2´-HO-BDE-68) were gifts from Göran
Marsh (Stockholm University, Stockholm,
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BACKGROUND: Previous studies have shown that polybrominated diphenyl ethers (PBDEs) behave
as weak estrogens in animal and cell culture bioassays. In vivo metabolites of PBDEs are suspected
to cause these effects. 
OBJECTIVES: To identify candidate metabolites, mouse plasma samples were collected after continu-
ous oral and subcutaneous exposure to DE-71, a widely used commercial pentabromodiphenyl
ether product, for 34 days.
METHODS: Samples were extracted, separated into neutral and phenolic fractions, and analyzed by
gas chromatographic mass spectrometry.
RESULTS: In the plasma samples of orally treated animals, 2,2´,4,4´,5,5´-hexabromodiphenyl ether
(BDE-153) represented 52% of total measurable PBDEs, whereas it represented only 4.3% in the
DE-71 mixture. This suggested that BDE-153 was more persistent than other congeners in mice.
Several metabolites were detected and quantitated: 2,4-dibromophenol, 2,4,5-tribromophenol, and
six hydroxylated PBDEs. The presence of the two phenols suggested cleavage of the ether bond of
2,2´,4,4´-tetrabromodiphenyl ether (BDE-47) and 2,2´,4,4´,5-pentabromodiphenyl ether
(BDE-99), respectively. The hydroxylated (HO)-PBDEs might come from hydroxylation or
debromination/hydroxylation. Among the quantitated hydroxylated metabolites, the most abun-
dant was 4-HO-2,2´,3,4´-tetra-BDE, which suggested that there was a bromine shift during the
hydroxylation process. para-HO-PBDEs have been proposed to behave as endocrine disruptors.
CONCLUSIONS: There seem to be three metabolic pathways: cleavage of the diphenyl ether bond,
hydroxylation, and debromination/hydroxylation. The cleavage of the diphenyl ether bond formed
bromophenols, and the other two pathways formed hydroxylated PBDEs, of which para-HO-
PBDEs are most likely formed from BDE-47. These metabolites may be the most thyroxine-like
and/or estrogen-like congeners among the HO-PBDEs.
KEY WORDS: BDE-153, bromophenols, DE-71, hydroxylated PBDEs, hydroxylation, polybrominated
diphenyl ethers. Environ Health Perspect 115:1052–1058 (2007). doi:10.1289/ehp.10011 available
via http://dx.doi.org/ [Online 6 April 2007]Sweden), and were synthesized as described
elsewhere (Marsh et al. 2004). 4-Methoxy-
2,2´,3,4´,5-penta-BDE (4-MeO-BDE-90);
5´-methoxy-2,2´,4,4´,5-penta-BDE (5´-MeO-
BDE-99); 6´-methoxy-2,2´,4,4´,5-penta-BDE
(6´-MeO-BDE-99); 2,3-dibromophenol
(2,3-DBP); 2,5-DBP, 3,5-DBP; and 2,4,6-
tribromophenol (2,4,6-TBP) were from
AccuStandard. 2,4-DBP; 2,6-DBP; 2,4,5-
TBP; and 4-HO-2,2´,3,4´,5,5´,6-hepta-BDE
(4-HO-PCB-187) were from Cambridge
Isotope Laboratories (Cambridge, MA).
All of the phenolic compounds were
methylated with fresh diazomethane, which
was prepared from Diazald (Sigma Chemical
Co.) (Black 1983). All the solvents used for
the extraction and cleanup procedures were
residue-analysis grade. 
Experimental design. All animal work was
approved by the Institutional Animal Care
and Use Committee at the Indiana University
School of Medicine, and the mice were
treated humanely and with regard for allevia-
tion of suffering in the experiment process.
Adult BALB/c mice were ovariectomized at
6–8 weeks of age. Starting 3 weeks after the
operation, the animals were treated ﬁve times
per week for 34 days with vehicle or test com-
pound. In brief, groups of ﬁve to six animals
were treated by either subcutaneous (sc) injec-
tion or oral gavage with vehicle control,
10 μg/kg β-estradiol-3-benzoate, or 45 mg/kg
DE-71. Some groups were treated with both
β-estradiol-3-benzoate and DE-71 at the
same time. Chemicals were first dissolved in
dimethyl sulfoxide and then diluted in corn
oil for a total dose volume of 0.1 mL for oral
gavage and 10–20 μL for sc injection. On the
day after the last treatment, the animals were
sacriﬁced by decapitation, and blood was col-
lected by exsanguination. Blood was kept at
4°C for ≤ 20 hr before it was centrifuged at
10,000 × g for 10 min at 4°C. The super-
natant plasma was collected and stored below
–20°C until analysis. Because we focused only
on the precursor congeners and metabolites of
DE-71 in this study, we divided the plasma
samples into three groups: oral gavage, sc
injection, and controls (plasma samples from
mice not treated with DE-71). 
Sample extraction and preparation. A
previous method (Hovander et al. 2000;
Malmberg et al. 2005) was modiﬁed slightly
to accommodate the smaller mouse plasma
samples in the present study. We transferred
each sample (range, 0.028–0.213 g, with an
average wet weight of 0.120 g) to a centrifuge
tube with a Teflon-lined screw cap. Known
amounts of BDE-77 and 4-HO-PCB-187
were added as surrogate standards to deter-
mine the recovery of both neutral and pheno-
lic target compounds. After adjustment to
2 mL with 1% potassium chloride, each sam-
ple was denatured with 0.5 mL hydrochloric
acid (6 M) and 3 mL 2-propanol. Samples
were extracted with hexane:methyl tert-butyl
ether (1:1, vol/vol) three times by shaking the
tube > 5 min each time. After blowing down
the combined extracts, the phenolic com-
pounds were separated from the neutrals by
partitioning with potassium hydroxide (0.5 M
in 50% ethanol). The aqueous phase was re-
extracted with hexane twice more. After acidi-
fication of the aqueous phase, the phenolic
compounds were extracted three times with
hexane:methyl tert-butyl ether (9:1, vol/vol).
The neutral fraction was treated with con-
centrated sulfuric acid, followed by alumina
column chromatography (0.6 cm i.d. × 6 cm,
with 0.5 cm anhydrous sodium sulfate on top).
The column was eluted with 8 mL hexane fol-
lowed by 8 mL hexane:dichloromethane (3:2,
vol/vol); the PBDE congeners eluted in the
second fraction. After concentration, BDE-71
was added as an internal standard for gas chro-
matographic mass spectrometry (GC/MS)
analysis.
The phenolic fraction was concentrated,
and the solvent was changed to hexane. To
methylate the hydroxyl group, the samples
were treated with an excess of a diazomethane
solution at room temperature for 3 hr, and
the solvent was removed by blowing it down
to near dryness. The samples were dissolved in
dichloromethane and purified on a column
with 0.5 g sulfuric acid–impregnated silica gel,
using 8 mL dichloromethane as the mobile
phase. After replacement of dichloromethane
with hexane, internal standards (1,3,5-tribro-
mobenzene for the methylated bromophenols
and BDE-71 for the methylated HO-PBDEs)
were added for GC/MS analysis.
In each batch of samples, at least two
blank samples (phosphate-buffered saline) or
control samples (plasma from untreated mice)
were prepared. To prevent photodegradation,
during the entire process the centrifuge tubes
remained wrapped with aluminum foil, or
amber vials were used. 
Instrumental analysis. We analyzed both
neutral and methylated phenolic fractions
using GC/MS [Agilent 6890/5973, with an
electron capture negative ionization (ECNI)
ion source (Agilent Technologies, Santa Clara,
CA)]. We used ECNI-selected ion monitoring
of m/z 79 and 81 for quantitation. GC injec-
tions (1 μL) were made in the pulse splitless
mode, with a purge time of 2.0 min. Both the
injection port and the transfer line were held
at 285°C. A 15-m DB-5-MS capillary column
(250 μm i.d., 0.25 μm film thickness; J&W
Scientiﬁc, Folsom, CA) was used for the neu-
tral fraction, with the following GC oven
temperature program: held at 100°C for
1 min; 20°C/min to 200°C; 8°C/min to
270°C; 25°C/min to 300°C; held for 3 min.
The same instrument, but with a longer
(60-m) column, was used for the methylated
phenolic fraction, with the oven temperature
program as follows: held at 60°C for 1 min;
3°C/min to 160°C; 15°C/min to 250°C;
2°C/min to 300°C; held for 10 min. We used
GC/MS with an electron impact ion source
and with a 30-m DB-5-MS column to obtain
electron impact mass spectra of target com-
pounds in the full-scan mode.
Results and Discussion
We detected and quantified all of the main
congeners in DE-71 (BDEs 47, 85, 99, 100,
153, and 154) and trace amounts of BDE-28
in the neutral fraction of the mouse plasma
samples. No methoxylated PBDEs (MeO-
PBDEs) were detected in the neutral fraction.
In the phenolic fraction, three bromophenols
(2,4-DBP, 2,4,5-TBP, and 2,4,6-TBP) and
six HO-PBDEs (4´-HO-BDE-17, 2´-HO-
BDE-28, 4-HO-BDE-42, 3-HO-BDE-47,
6-HO-BDE-47, and 4´-HO-BDE-49) were
identified and quantified. 4-HO-BDE-90
was identified but not quantified because of
co-elution with another peak. Several other
potential phenolic metabolites (5-HO-
BDE-47, 2´-HO-BDE-68, 6´-HO-BDE-
99, 5´-HO-BDE-99, 2,3-DBP, 2,5-DBP,
2,6-DBP, and 3,5-DBP) were not detected.
The concentration data for the neutral and
phenolic compounds are presented in
Table 1.
By using a nonpolar capillary column
(such as DB-5) to separate the methylated
HO-PBDEs, 2´-HO-BDE-66 will co-elute
with 3-HO-BDE-47 (Marsh et al. 2006).
However, based on its mass spectrum, the
GC peak we observed should be mainly the
methyl derivative of 3-HO-BDE-47. Marsh
et al. (2006) also reported that the concentra-
tion of 2´-HO-BDE-66 was much lower than
that of 3-HO-BDE-47 in rat feces after rats
were exposed to BDE-47. Thus, in this study
we did not determine the concentration of
2´-HO-BDE-66.
The amounts of most target compounds
in the blank samples were negligible except for
2,4,6-TBP, for which the blank average con-
centration was > 50% of that measured in the
exposed samples. Relatively high blank con-
centrations of 2,4,6-TBP are reasonable
because this compound is the most common
TBP isomer. The recoveries (mean ± SD) of
surrogate standards were 96 ± 7% for BDE-77
and 96 ± 5% for 4-HO-PCB-187.
Neutral compounds. DE-71 is commercial
penta-BDE, and its main components are
BDE-47 and BDE-99 in about equal amounts.
Some other significant congeners, such as
BDEs 100, 153, and 154 (Table 1), are also
present in this commercial product. To evalu-
ate the behavior of these congeners in mouse
blood, we normalized their concentrations to
that of BDE-99 in DE-71 and in mouse
plasma as shown in Figure 1.
PBDE metabolites in mice
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of BDEs 47, 100, and 154 are about the same
in mouse plasma as in DE-71. However,
BDE-153 behaved quite differently. The ratio
of BDE-153 to BDE-99 was < 10% in DE-71;
however, this ratio increased to 88 ± 24% in
plasma samples following sc injection, and it
increased to 270 ± 93% after oral gavage.
BDEs 47, 99, and 153 represented 18, 19,
and 52%, respectively, of total measurable
PBDEs in oral gavage samples, whereas they
represented 36, 44, and 4.3% of the total in
the DE-71 mixture (Table 1). The increased
ratio of BDE-153 suggests that this com-
pound was poorly metabolized or otherwise
highly persistent in mice. 
In orally exposed mice, two factors might
influence the concentration of PBDEs in
blood: uptake efficiency and removal rate.
Burreau et al. (1997) reported uptake efﬁcien-
cies of 90, 60, and 40% for BDEs 47, 99, and
153, respectively, in pike (Esox lucius) fed a
mixture of these compounds. Other researchers
also showed that BDE-153 was less absorbed
than BDE-47 and BDE-99 in rats and mice
following gavage (Chen et al. 2006; Sanders
et al. 2006a, 2006b). The uptake efﬁciency for
BDE-153 was lower than that of BDE-47 and
BDE-99, probably because of its larger size.
Two processes are able to remove PBDEs
from blood: distribution between blood and
other tissue (mainly adipose tissue) and
metabolism. Because adipose tissue is the main
tissue sink of BDE-153 in mice (Staskal et al.
2006) and because others have found either
similar BDE-99 and BDE-153 distributions to
adipose tissue (Sanders et al. 2006b) or higher
adipose tissue distribution for BDE-153 than
for BDE-99 or BDE-47 (Staskal et al. 2006)
in exposed rodents, it seems that sequestration
to tissues cannot explain the higher blood
concentration of BDE-153 compared to
BDE-99. Furthermore, both uptake and dis-
tribution are biophysical processes, which are
likely to have little isomer selectivity. For
example, BDE-154 and BDE-153 should have
almost the same absorption and distribution
behavior because these two isomers are close in
structure and in their physicochemical proper-
ties, especially their Kow values (Braekevelt
et al. 2003). We found no relative increase of
BDE-154 in mouse plasma samples compared
with its relative concentration in DE-71
(Table 1, Figure 1); therefore, differential
metabolism is the more likely explanation for
the accumulation of BDE-153 in mice.
Metabolic enzymes, which might have
high isomer selectivity, could determine the
concentration pattern of congeners in tissues,
as well as their fate and potential toxicity
(Hakk and Letcher 2003). In mammals, the
liver is the main site where xenobiotic chemi-
cals are metabolized. High concentrations 
of BDE-153 in blood might suggest that
BDE-153 was resistant to enzyme degradation
in mouse liver. Sanders et al. (2006b) reported
that when rats were exposed to a mixture of
BDE-47, BDE-99, and BDE-153, the concen-
tration of BDE-153 in liver was three times
higher than that of BDE-47 and BDE-99. 
BDE-153 was only a minor component in
both commercial penta-BDE and octa-BDE
technical mixtures (Birnbaum and Staskal
2004). In ﬁeld samples, such as sediment and
ambient and indoor air, no obvious evidence
of BDE-153 accumulation was found when
compared to BDE-47 and BDE-99 (Hites
2004). This is expected for congeners that have
comparable environmental fates; that is, they
have similar physicochemical pathways from
their sources to the environmental media from
which they are sampled. Conversely, relatively
high concentrations of BDE-153 have been
measured in samples from some wild animals
and humans, especially in liver and blood
(plasma or serum) samples. Voorspoels et al.
(2006) reported that, in the liver of red foxes
from Belgium, the concentration of BDE-153
was > 10 times higher than that of BDE-99
and 3 times higher than that of BDE-47.
Recently, relatively high concentrations of
BDE-153 were also observed in human sera,
especially from the Netherlands and Sweden
(Weiss et al. 2004, 2006).
Although it has been proposed that
debromination of BDE-209 may be a source of
BDE-153 (Weiss et al. 2006), at present there
is no evidence to support this hypothesis.
Qiu et al.
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Table 1. Concentrations (ng/g wet weight) of neutral and phenolic compounds in mouse plasma. 
Oral gavage  sc injection  Blank and control 
samples (n = 15) samples (n = 14) samples (n = 19)
Compound/congener Mean ± SD Percent of total Mean ± SD Percent of total Mean ± SD
Neutral compoundsa
BDE-28 (0.3) 4.4 ± 1.1 0.2 5.3 ± 1.6 0.5 0.6 ± 0.8
BDE-47 (36) 390 ± 100 18 360 ± 77 31 3.0 ± 6.3
BDE-85 (2.6) 57 ± 19 2.6 32 ± 5 2.8 ND
BDE-99 (44) 410 ± 120 19 330 ± 70 29 2.3 ± 3.9
BDE-100 (9.1) 140 ± 40 6.4 110 ± 20 9.2 0.4 ± 1.3
BDE-153 (4.3) 1,100 ± 380 52 290 ± 80 25 0.6 ± 0.8
BDE-154 (3.3) 22 ± 7 1.0 20 ± 4 1.7 0.1 ± 0.2
Total 2,150 ± 410 100 1,150 ± 130 100
Phenolic compounds
2,4-DBP 72 ± 23 15 62 ± 25 17 1.4 ± 3.8
2,4,5-TBP 79 ± 29 16 86 ± 40 24 0.3 ± 0.6
2,4,6-TBP 5.3 ± 3.4 1.1 6.0 ± 6.0 1.6 3.3 ± 3.2
4´-HO-BDE-17 17 ± 10 3.5 11 ± 7 3.0 ND
2´-HO-BDE-28 11 ± 6 2.3 5.2 ± 2.5 1.4 0.1 ± 0.2
4-HO-BDE-42 180 ± 120 38 120 ± 88 32 1.1 ± 2.7
3-HO-BDE-47 53 ± 25 11 33 ± 17 9.1 ND
6-HO-BDE-47 22 ± 12 4.6 8.5 ± 4.0 2.3 ND
4´-HO-BDE-49 42 ± 22 8.7 34 ± 19 9.3 0.3 ± 0.8
Total 480 ± 130 100 360 ± 104 100
ND, not detected.
aCongeners (percentages) found in DE-71.
Figure 1. Concentration ratio (%) of neutral congeners normalized to BDE-99 = 100% in DE-71 and mouse
plasma samples. Error bars indicate SD.
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DE-71 Oral gavage sc injectionWhen carp were exposed to BDE-209, the
congeners BDE-154, BDE-155, and another
unidentified hexa-BDE were the three main
hexabrominated products (Stapleton et al.
2006a), suggesting that BDE-153 was not
preferentially formed from BDE-209, at least
in ﬁsh. In the present study, BDE-209 was not
present to serve as a precursor of BDE-153.
Therefore, resistance to enzyme degradation is
likely to be the most important cause of the
increased relative concentration of BDE-153
observed in various animals.
Phenolic compounds. HO-PBDEs are
metabolites of PBDEs in animals, and they can
also occur in marine environments as natural
products (Malmvärn et al. 2005a). These com-
pounds have been observed in animals from
in vivo experiments (Malmberg et al. 2005;
Marsh et al. 2006) and in ﬁeld samples (some-
time in the form of methylated derivatives)
(Malmvärn et al. 2005a, 2005b; Marsh et al.
2004; Stapleton et al. 2006b; Valters et al.
2005). In the present study, we identified
many phenolic metabolites, limited only by the
availability of standards. Based on the metabo-
lites we measured, there seem to be three main
metabolic pathways for PBDEs in mice: cleav-
age of the diphenyl ether bond, hydroxylation,
and debromination/hydroxylation. 
Table 1 lists the phenolic compounds
measured in the mouse plasma samples,
including their concentrations in animals
dosed by oral gavage and by sc injection. All
of these metabolites were identiﬁed not only
by comparing their retention times to those of
authentic standards but also from their mass
spectra, which were obtained using GC/MS
with an electron impact ion source operating
in full-scan mode.
Cleavage of the diphenyl ether bond.
Most recent research has focused on the
hydroxylated PBDE metabolites, but few arti-
cles have reported diphenyl ether bond cleav-
age. Omitting 2,4,6-TBP because of blank
interferences, we have identiﬁed two bromo-
phenol metabolites (2,4-DBP and 2,4,5-TBP),
which could only be obtained through the
cleavage of the diphenyl ether bond. These
bromophenols were detected at concentrations
higher than most of the two-ring hydroxyla-
tion products (Table 1), suggesting that
diphenyl ether bond cleavage is an important
metabolic pathway for PBDEs in mice.
Previous studies have reported the cleavage
of the diphenyl ether bond of PBDEs in the
gas phase (Raff and Hites 2006) and of a
PBDE-like thyropropionic acid in solution
(Matsuura et al. 1971). The mechanism pro-
posed for such reactions involves a HO radical
attacking the carbon–oxygen bond. A similar
mechanism has been reported to cleave the
thyroxine diphenyl ether bond in vitro by
incubation with rat liver homogenates (Balsam
et al. 1983). In the case of PBDEs, the inter-
mediate product then cleaves into a bromi-
nated phenol and a phenoxy radical, which
can abstract hydrogen to form another bromi-
nated phenol. In this potential pathway,
2,4,5-TBP could come mainly from BDE-99,
whereas 2,4-DBP could come from both
BDE-47 and BDE-99; therefore, the concen-
tration of 2,4-DBP would be expected to be
greater than that of 2,4,5-TBP. However, our
measurements showed a concentration ratio of
2,4-DBP to 2,4,5-TBP of 0.89 (the molecular
ratio was 1.2), which is near the concentration
ratio of BDE-47 to BDE-99 in DE-71 (0.82;
the molecular ratio was 0.96). Although the
ratio of 2,4-DBP to 2,4,5-TBP might be
influenced by different residence times of
these two compounds in blood, this ratio
could also suggest the occurrence of another
metabolic step in animals that does not occur
in the gas phase or in solution. For example,
BDE-99 could produce one molecule of
2,4,5-TBP and one molecule of 3,5-dibromo-
catechol (3,5-DBC) through an arene oxide
intermediate (Chen et al. 2006), and BDE-47
could produce 2,4-DBP and 3,5-DBC, as
shown in Figure 2.
The same degradation pathway was pro-
posed by Schmidt et al. (1993) when halo-
genated diphenyl ethers were degraded by the
bacterium Sphingomonas sp. Strain SS3. In
fact, the bacterial scission of ether bonds is an
important degradation pathway for com-
pounds with ether linkages in the environ-
ment, including diphenyl ethers (White et al.
1996). We suggest that this pathway is
important not only in bacterial degradation
but also in mammals. However, at present
there are no reports in the literature of bro-
mocatechol as a PBDE metabolite in rodents
or in other animals. Because there was no
standard available for 3,5-DBC, we did not
measure this compound. Identification of
3,5-DBC as an animal metabolite in future
studies will help further our understanding of
the cleavage of the diphenyl ether bond in
PBDEs.
Hydroxylation. Hydroxylation is an
important metabolic pathway for PBDEs in
animals. We identiﬁed and quantitated almost
all possible HO-tetra-BDE peaks in mouse
plasma (Table 1). If we assume that all HO-
tetra-PBDEs came from arene oxide intermedi-
ates of BDE-47 and that all of these
HO-PBDEs have the same residence time in
mouse blood, then we can propose a metabolic
pathway and estimate the product proportions
as shown in Figure 3.
Another potential metabolite, 2´-HO-
BDE-68, was not detected, suggesting that
there was no possible way to form this com-
pound from BDE-47 (Figure 4).
We suspect that hydroxylation of PBDEs
is mediated by cytochrome P450 enzymes,
which can account for direct hydroxylation or
hydroxylation via a 1,2-shift. The 1,2-shift
mechanism proceeds via an arene oxide inter-
mediate (Guroff et al. 1967; Jerina and Daly
1974). Obviously, 4-HO-BDE-42 and
4´-HO-BDE-49 must have been formed
through a 1,2-shift. The methylated products
PBDE metabolites in mice
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Figure 2. Proposed pathway of the cleavage of the diphenyl ether bond of BDE-47 and BDE-99 in mice.
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3,5-DBCof 4-HO-BDE-42 and 4´-HO-BDE-49 have
also been measured in field samples (Valters
et al. 2005). It is notable that these para-HO-
PBDEs in our samples totaled > 75% of the
total measurable HO-tetra-BDE metabolites.
This suggests that when the hydroxylation of
BDE-47 occurred, the HO group was more
likely to transfer to the para position of the
phenyl ring with a 1,2-shift of the original
para-bromine atom. 6-HO-BDE-47 was pre-
sent at a low abundance (6%), and 5-HO-
BDE-47 was not detected. Overall, our results
suggest that hydroxylation has a preference
for the para position as opposed to the ortho
or meta positions.
The high proportion of some HO-PBDEs,
such as 4-HO-BDE-42, suggests that either
they were preferentially formed or were more
persistent in mouse blood. These metabolites
might have a substantial biological effect. For
example, three HO-PBDE congeners (4-HO-
BDE-42, 4´-HO-BDE-49, and 3-HO-BDE-
47) were shown to have up to a four times
stronger afﬁnity to TTR than does thyroxine
(Malmberg et al. 2005). This suggested that
para-HO-PBDEs might be the most thyroxine-
like HO-PBDEs. In any case, the preferential
formation and/or persistence of para-HO-
PBDEs in mice suggests these compounds
should receive more toxicologic attention. 
As discussed above, we assumed that
HO-tetra-BDEs result from the hydroxyla-
tion of BDE-47. HO-PBDEs could also
result from debromination/hydroxylation
reactions of BDE-99, but these reactions may
be less important than hydroxylation alone.
Moreover, by comparing the structure of
HO-tetra-BDEs, such as 4-HO-BDE-42,
with BDE-47 and BDE-99, it is apparent that
these HO-tetra-BDEs more likely come from
hydroxylation of BDE-47 rather than from
debromination/hydroxylation of BDE-99
(Figure 5).
In addition to the mono-hydroxylated
tetra-BDEs, one dihydroxylated tetra-BDE
was identiﬁed through its mass spectrum, but
we were unable to determine its substitution
pattern. Others have made a similar observa-
tion (Malmberg et al. 2005). 
For the three HO-penta-BDE isomers for
which we had standards (5´-HO-BDE-99,
6´-HO-BDE-99, and 4-HO-BDE-90), only
4-HO-BDE-90 was detected, but we found
two other relatively abundant GC peaks cor-
responding to other HO-penta-BDEs, which
together could represent the most abundant
HO-penta-BDEs (Figure 6). 
The electron impact mass spectra of these
two peaks indicated that the hydroxyl group
was in the meta-position of the phenyl ring.
We observed ions due to [M]+, [M–2Br]+, and
[M–2Br–CH3]+, which were consistent with a
methylated derivative of a meta-HO-BDE
structure as described by Malmberg et al.
(2005). The preferential formation of meta-
HO-BDEs from a penta-BDE, presumably
BDE-99, was quite different from the hydrox-
ylation of BDE-47, for which para-HO-BDEs
were the major metabolites.
Debromination/hydroxylation. The
metabolic pathway of debromination/
hydroxylation has also been observed in other
studies. When rats were exposed to BDE-47,
three kinds of HO-tri-BDE were found in
feces (Marsh et al. 2006). In the present study,
we found and quantitated two HO-tri-BDEs
(4´-HO-BDE-17 and 2´-HO-BDE-28).
Although we found trace amounts of BDE-28
Qiu et al.
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Figure 4. BDE-47 cannot be metabolized to 2´-HO-BDE-68.
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Figure 3. Proposed hydroxylation pathway of BDE-47 in mice and the percentage of metabolites based on
the measurements in this study. ND, not detected.
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Hin commercial DE-71 and it was detected in
mouse plasma, the concentration of BDE-28
was much lower than those of 4´-HO-BDE-17
and 2´-HO-BDE-28 (Table 1). It is more rea-
sonable to believe that these two isomers were
formed by the debromination/hydroxylation
of a more abundant congener, such as
BDE-47, rather than by hydroxylation of
BDE-28 (Figure 7).
Moreover, although there might be a
1,2-shift during the hydroxylation process
and bromine could shift to the adjacent
position on the phenyl ring, at present there
is no indication that bromine can shift from
a para position to an ortho position. In other
words, 4´-HO-BDE-17 could not be formed
from BDE-28, leaving debromination/
hydroxylation of a more brominated BDE
(such as BDE-47) as the more likely pathway
(Figure 7). 
Compared with those metabolites formed
through direct hydroxylation, the concentration
of metabolites formed by debromination/
hydroxylation was low (Table 1), which sug-
gests that hydroxylation is a more important
process than debromination/hydroxylation, at
least for tetra-BDE. 
Conclusion
BDE-153 accumulates in the blood of mice
exposed to commercial DE-71, suggesting
that this compound might be resistant to
enzymatic degradation. For the other PBDE
congeners in DE-71, there seem to be three
metabolic pathways: cleavage of the diphenyl
ether bond, hydroxylation, and debromina-
tion/hydroxylation. The cleavage of the
diphenyl ether bond forms bromophenols,
whereas the other two pathways form
HO-PBDEs, in some cases with a 1,2-shift of
the original para-bromine atom. In this path-
way, para-HO-PBDEs are most likely formed
from BDE-47; these metabolites could be the
most thyroxine-like and/or estrogen-like
congeners among the HO-PBDEs.
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Figure 5. BDE-99 cannot be metabolized to 4-HO-BDE-42.
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Figure 7. Debromination/hydroxylation of BDE-47 can give two hydroxylated tri-BDEs, but BDE-28 cannot.
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CORRECTION
In Figure 3 of the original manuscript
published online, the arrows indicating
pathways were incorrect. They have been
corrected here.Qiu et al.
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